Arthritis Res Ther. 2010;12(4):138. doi: 10.1186/ar3114. Epub 2010 Aug 26.
The IFN-I pathway is activated in systemic lupus erythematosus (SLE) and appears to be important in the pathogenesis of the disease. As a result, several clinical trials of anti-IFN monoclonal antibodies, which hold promise to control the disease, have been launched. Additionally, activation of IFN-I might be important in the prognosis and activity assessment of the disease. Therefore, new biomarkers that reflect activity of the IFN-I pathway and are simple to measure, such as the monocyte CD64 receptor, are expected to have a great impact on the management of SLE, if properly validated.
IFN-I 通路在系统性红斑狼疮（SLE）中被激活，并且似乎在疾病的发病机制中起重要作用。因此，已经启动了几项针对抗 IFN 单克隆抗体的临床试验，这些抗体有望控制疾病。此外，IFN-I 的激活可能对疾病的预后和活动评估很重要。因此，如果经过适当验证，新的生物标志物，如单核细胞 CD64 受体，反映 IFN-I 通路的活性且易于测量，有望对 SLE 的治疗产生重大影响。
